Januvia price-listed and set for launch in Japan
This article was originally published in Scrip
Executive Summary
Merck & Co's DPP-4 inhibitor Januvia (sitagliptin) has received a reimbursement price in Japan, clearing the way for its launch as the first drug in its class in the country once it is included in the tariff on December 11th.